Skip to content

Acadia Pharmaceuticals ACAD Gain (loss) on disposal of assets

Gain (loss) on disposal of assets at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfIntangibleAssets.

The official record: Acadia Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's gain (loss) on disposal of assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's gain (loss) on disposal of assets?
Acadia Pharmaceuticals (ACAD) reported gain (loss) on disposal of assets of $0 in Q4 2025.
How has Acadia Pharmaceuticals's gain (loss) on disposal of assets changed year-over-year?
Acadia Pharmaceuticals's gain (loss) on disposal of assets decreased by 100.0% year-over-year, from $36.63M to $0.
What does gain (loss) on disposal of assets mean?
Gains or losses recognized on the disposal of businesses, property, equipment, investments, or other assets at prices above or below their carrying value.